TEL AVIV, Israel -- (BUSINESS WIRE) -- Compugen Ltd. (NASDAQ: CGEN) today announced that its scientists are presenting at three international cancer conferences next month:
Cancer Progress, March 4-5, 2014 in New York, NY
Galit Rotman, PhD, Chief Scientist of Therapeutics, Compugen: Taking Immunotherapy Seriously: New Targets and Combinations
Immune Evolution in Cancer, March 9-13 in Whistler, British Columbia, Canada
Ofer Levy, PhD, Principal Scientist, Compugen: Identification of Novel Immune Checkpoints as Potential Targets for Cancer Immunotherapy
1st Immunotherapy of Cancer Conference, March 12-14 in Munich, Germany
Gady Cojocaru, PhD, Principal Scientist, Compugen: Identification of Novel Immune Checkpoints as Targets for Cancer Immunotherapy
Anat Cohen-Dayag, PhD, President and CEO of Compugen, stated, “As the scientific and medical communities’ belief that cancer immunotherapy represents a paradigm shift in cancer treatment becomes more widely validated, numerous international scientific conferences have been scheduled to highlight the exciting advances being made. With respect to Compugen, we are very pleased to see the growing recognition of our cancer immunotherapy related accomplishments and programs as demonstrated in part by our participation in these conferences. In the first half of March, Compugen scientists will be presenting at three separate meetings relating to cancer immunotherapy: Cancer Progress, organized by Defined Health in New York; Immune Evolution in Cancer, a Keystone Symposia event in Whistler, Canada; and the Immunotherapy of Cancer Conference being held in Munich, Germany.”
Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. Compugen’s wholly-owned U.S. subsidiary located in South San Francisco is developing oncology and immunology monoclonal antibody therapeutic candidates against its drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of terminology such as “will,” “may,” “expects,” “anticipates,” “believes,” and “intends,” and describe opinions about future events. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Some of these risks are: changes in relationships with collaborators; the inability to reach mutually agreeable terms and conditions with respect to potential new collaborations, the impact of competitive products and technological changes; risks relating to the development of new products; and the ability to implement technological improvements. These and other factors are discussed in the "Risk Factors" section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.